Previous 10 | Next 10 |
By Wvan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group, and Wendy Lam, Ph.D., Portfolio Manager and Research Analyst, Franklin Biotechnology Discovery Fund Innovation has always been a key driver for the biotechnology industry. Even in the midst of the CO...
In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...
I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...
Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable? In a recent mark...
By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...
Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...
It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...
Brookfield Asset Management's ( BAM ) global scale and its diversified portfolio offerings stand to benefit immensely from favorable asset management trends such as mandates tilting toward global platforms and capital chasing yields in alternative asset classes at a faster pace than ever befor...
Aprea Therapeutics (NASDAQ: APRE ) opens for trading after raising the size of its IPO to 5.67M shares from 5M and pricing its IPO at $15 , the mid‐point of the $14‐$16 expected range. More news on: Aprea Therapeutics, Monopar Therapeutics, ADC Therapeutics SA, Healthcare st...
The Healthcare sector ranks fourth out of the 11 sectors as detailed in our Q3'19 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked fifth. It gets our Neutral rating, which is based on an aggregation of ratings of the 322 stocks in the Healthcare...
News, Short Squeeze, Breakout and More Instantly...
Virtus LifeSci Biotech Products Company Name:
BBP Stock Symbol:
NYSE Market:
2024-03-31 00:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-20 22:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-10 20:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...